Tobias Poehlmann, Biologist by training, did his PhD in cancer biology investigating the effect of silencing genes involved in cell signaling in cancer cells. Involved in the European Network of Excellence “EMBIC” he intensified his knowledge in the field of silencing oligonucleotides and built his scientific network. As an independent researcher he stepped in the field of therapeutic oligonucleotides, developed the technology of peptide-siRNA prodrugs and Co-founded several companies focused on oligonucleotide drug development and GMP manufacturing. Tobias is a university lecturer and enthusiastic oligonucleotides scientist.